Pandorum is a pioneering biotechnology company operating across the US and India, dedicated to advancing the fields of Tissue Engineering and Regenerative Medicine. Their proprietary technology platform uniquely integrates therapeutic exosomes—engineered with anti-inflammatory and anti-fibrotic properties from clinical-grade human stem cells—with biomaterials that closely mimic natural human tissues. This powerful synergy enables efficient regeneration of critical organs such as the cornea, liver, and lung. Supported by prestigious government grants, leading investors, and world-class medical institutions including Northwestern Medicine, the Medical University of South Carolina, and Dr. Shroff’s Charity Eye Hospital, they continue to push the boundaries of clinical translation. As part of NYU Stern’s Endless Frontier Labs Life Sciences Cohort 2023, Pandorum’s mission is to make regenerative medicine a scalable, impactful reality—bringing hope, healing, and advanced therapeutic possibilities to millions worldwide.